Last updated: 2026-11-14 04:20:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Annovis Bio, Inc. (ANVS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $0.92, with a market capitalization of $36.45M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.62 to $5.50. This page covers its latest market performance, valuation, price trends and company information.
$36.45M | |
$0.89 | |
$0.95 | |
$0.82 | |
$0.85 | |
2.12M | |
1.72M | |
-- | |
$5.50 | |
$0.62 | |
-- | |
-- |
Annovis Bio, Inc. (ANVS) last closed at $0.92 as of 2026-11-14 00:30:21, up 8.79% ($0.07) from the previous close of $0.85.
During the latest regular trading session, ANVS traded between $0.82 and $0.95, with a volume of 2.12M shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Annovis Bio, Inc. (ANVS) moved from $0.67 to $0.92, representing a gain of 37.39% ($0.25).
The stock traded between $0.62 and $0.99 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 7.46 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 6.2%
ANVS is currently trading at $0.92, placing it 6.2% of the way from its 52-week low of $0.62 to its 52-week high of $5.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NYSE |
| Company Website |
Latest news related to Annovis Bio, Inc. and ANVS stock.
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.32) by 31.25 percent. This is a 40.54 percent increase over losses of $(0.37) per share from the
Eligible investors can buy real shares of Annovis Bio, Inc. (ANVS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Browse other US stocks in the same sector as Annovis Bio, Inc.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ANVS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ANVS shares and USD.
ANVS Shares to USD
1.00 ANVS shares = 0.919 USD
Calculations are estimates based on the latest available price and are for reference only.
